Mereo Biopharma Group in brief
Mereo Biopharma Group is a listed company in the Biotechnology industry, based in the UK. Its last known market value was $400 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $0 M and a net profit of $42 M. It employs about 39 people. Its shares trade under the symbol MAH0.SG (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Mereo Biopharma Group
We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical product candidates. Our late-stage rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta and alvelestat for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease. Setrusumab has received orphan designation for OI from the European Commission and the FDA, PRIME designation from the EMA and has Breakthrough Therapy designation and rare pediatric disease designation from the FDA. Alvelestat has received orphan designation for AATD from the EC and the FDA, and Fast Track designation for the treatment of AATD-LD from the FDA. We also have an early-stage rare disease program, vantictumab, for the treatment of a second bone disease, autosomal dominant osteopetrosis Type 2. The global development of vantictumab is being funded and led by our partner, āshibio, and we retain the European commercial rights.
Market cap history
World rank over time
Rank in UK: #476 (Jan 2020) · #623 (Jan 2021) · #884 (Jan 2022) · #911 (Dec 2022) · #778 (Jul 2023) · #485 (Jan 2024)
Key ratios
- P/E ratio
- —
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- 8376.0%
- Operating margin
- -8022.0%
- Return on equity
- 102.3%
- Liabilities / assets
- 10.9%
- Revenue per employee
- $13 K
- Profit per employee
- $1.1 M
Annual results
- Revenue
- $1 M
- Operating income
- $-40 M
- Net income
- $42 M
For year ending December-2025
Balance sheet
- Total assets
- $46 M
- Total liabilities
- $5 M
- Total equity
- $41 M
As of December-2025
How Mereo Biopharma Group compares in Biotechnology
- Revenue$1 M · higher than 21% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Mereo Biopharma Group🇬🇧 | $400 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 15, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Mereo Biopharma Group? Verify and update this profile — free
Show Mereo Biopharma Group's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.